Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity

Alexandros Ardavanis, Stella Koumna, Ioannis Fragos, Savvoula Malliou, Flora Kyriakou, Ioannis Mantzaris, Andreas Scorilas, Gerassimos Rigatos

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81%) male, 7 (19%) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7%, while the disease control rate was 81%. Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.

Original languageEnglish (US)
Pages (from-to)2409-2415
Number of pages7
JournalAnticancer Research
Volume28
Issue number4 C
StatePublished - Jul 1 2008
Externally publishedYes

Keywords

  • Advanced non-small cell lung cancer
  • Erlotinib
  • Monotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity'. Together they form a unique fingerprint.

  • Cite this

    Ardavanis, A., Koumna, S., Fragos, I., Malliou, S., Kyriakou, F., Mantzaris, I., Scorilas, A., & Rigatos, G. (2008). Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity. Anticancer Research, 28(4 C), 2409-2415.